Hindustan Bio Sciences Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 09, 2026

Key Highlights

The Latest Trading Price of Hindustan Bio Sciences Ltd is ₹ 9.08 as of 08 May 15:30 . The P/E Ratio of Hindustan Bio Sciences Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Hindustan Bio Sciences Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Hindustan Bio Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Hindustan Bio Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Limited was initially incorporated as Garuda Cements Limited in December 1991.
Earlier, it was engaged in cement manufacturing and due to sluggish in the industry, the Company diversified its business into Bio Technology & Pharmaceuticals activities in 2000-01 and the name was changed from Garuda Cements Limited to Hindustan Bio-Sciences Limited.
In 2002, it diversified into software field and subsequently changed its name to Hindustan Bio Sciences Limited on August 8, 2002. The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified businesses in pharmaceutical and biotechnology industries.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Hindustan Bio Sciences Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Hindustan Bio Sciences Ltd or Syncom Formulations (India) Ltd?

Market cap of Hindustan Bio Sciences Ltd is 9 Cr while Market cap of Syncom Formulations (India) Ltd is 1,382 Cr

What are the key factors driving the stock performance of Hindustan Bio Sciences Ltd and Syncom Formulations (India) Ltd?

The stock performance of Hindustan Bio Sciences Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hindustan Bio Sciences Ltd and Syncom Formulations (India) Ltd?

As of May 9, 2026, the Hindustan Bio Sciences Ltd stock price is INR ₹9.08. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.71.

How do dividend payouts of Hindustan Bio Sciences Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Hindustan Bio Sciences Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.